Q Fever (Coxiella burnetii)
Clinical Snapshot
Q fever is caused by Coxiella burnetii, a pleomorphic, gram-negative, obligate intracellular bacterium that replicates inside the acidified phagolysosome of infected cells. It exists in two forms: a metabolically active large-cell variant, and a spore-like small-cell variant that is extraordinarily resistant to heat, desiccation, ultraviolet light, and most chemical disinfectants — a property that lets it persist in soil, dust, and contaminated buildings for months to years and become airborne on wind currents.[1][2]
The single most important epidemiologic fact in this chapter: the highest numbers of organisms are shed in the birth products of infected animals. Cattle, sheep, and goats are the primary reservoirs, and an infected, otherwise-healthy-appearing animal can shed massive quantities of C. burnetii in amniotic fluid, placental tissue, and birth fluids at parturition, contaminating dust that is then inhaled — sometimes by people who never had direct contact with the animal itself.[2][3] A history of assisting a birth, cleaning a barn, or simply living near a farm that houses pregnant ewes or dairy goats is a genuinely important, specific detail to elicit — one outbreak documented cases in people living up to 16 km downwind of the source farm.[2] Unpasteurized milk and dairy products are a second, real but less common transmission route, since raw milk from infected cattle or goats can contain viable organisms.[3][1] Direct or indirect contact with infected cats, dogs, and other pets — again, particularly around parturition — has also caused documented outbreaks in North America.[1][2]
Absence of an obvious exposure history does not exclude the diagnosis. In U.S. surveillance data, 79% of reported cases occurred in patients without a recognized high-risk occupation, and 60% reported no livestock contact at all — airborne transmission means a compatible illness can occur without any direct animal exposure.[2]
Roughly half of infections are symptomatic.[2] Acute Q fever is typically a self-limited febrile illness that may present as atypical pneumonia or hepatitis, usually resolving within two to three weeks even without treatment, and responds well to doxycycline.[2][3] Chronic Q fever is rare — occurring in under 5% of infected people — but is a genuinely high-stakes complication: it develops almost exclusively in patients with pre-existing valvular or vascular disease, presents overwhelmingly as culture-negative endocarditis, and is invariably fatal without years of combination antibiotic therapy.[2][3]
Treat acute Q fever on clinical suspicion — never wait for serology to confirm the diagnosis. Definitive serologic confirmation requires paired acute and convalescent samples taken three to six weeks apart, which makes it primarily a retrospective diagnosis. Early doxycycline (ideally within the first 3 days of symptoms) shortens the illness and reduces the risk of severe complications; antibiotic treatment should never be withheld pending laboratory results or discontinued because of a negative early test.[2][3]
Recognize the Condition
Incubation period
The incubation period is dose-dependent, ranging from about 9 to 39 days but typically 14 to 22 days by respiratory (inhalational) exposure; it is generally described more simply as 2-3 weeks.[3][2] A smaller infectious dose — as can occur with long-distance windborne transmission — tends to produce a longer incubation period.[3] As few as 1-10 organisms are sufficient to cause infection.[1]
Acute Q fever in adults
Symptomatic acute Q fever produces a nonspecific febrile illness: fever, fatigue, chills, and myalgia are the most frequently reported symptoms. Headache is often severe and debilitating, sometimes retro-orbital with photophobia, and has been mistaken for a new-onset migraine or an infected tooth because the pain can radiate to the jaw.[2] Untreated fever lasts a median of 10 days (range 5-57 days) and tends to last longer in patients over 40; the majority of treated patients defervesce within 72 hours of starting doxycycline.[2] A maculopapular or purpuric rash occurs in only about 5-21% of adults.[2]
Atypical pneumonia and hepatitis — the two dominant organ-specific presentations
Pneumonia is caused by inhalation of contaminated aerosols and is, notably, the main clinical manifestation of Q fever in Canada (as well as Switzerland, the United Kingdom, and Spain).[1] It typically presents as a nonproductive cough with fever and only minimal findings on auscultation; chest radiographs are abnormal in the majority of patients (segmental or lobar consolidation, unilateral or bilateral) but the pattern cannot be distinguished from other causes of community-acquired pneumonia by any clinical, radiographic, or routine laboratory finding.[2] Hepatitis is the dominant presentation in France, Australia, and southern Spain, and can appear as an infectious-hepatitis-like illness with hepatomegaly, a clinically silent transaminitis, or granulomatous hepatitis; fever, abdominal pain, nausea, vomiting, and diarrhea are the main associated symptoms, though jaundice itself is rare.[1][2] Elevated liver enzymes are seen in up to 85% of acute cases regardless of whether hepatitis is the dominant clinical picture.[2]
Laboratory clues
Most patients have a normal white blood cell count, though up to 25% show leukocytosis. Mild thrombocytopenia is common early in illness (roughly one third of patients) and may be followed by a rebound thrombocytosis. Increased ESR, CRP, and creatine kinase, and hyponatremia, are also reported. Q fever causes enough immune activation that it can cause false-positive cross-reactivity on unrelated serologic tests, including ANCA, HIV, brucellosis, and rapid plasma reagin assays.[2]
Children
Children generally have milder illness than adults and are less likely to be symptomatic at all. Gastrointestinal symptoms — diarrhea, vomiting, abdominal pain, anorexia — are reported in 50-80% of pediatric cases, and a rash is considerably more common in children than in adults (up to 50% of diagnosed pediatric cases). Illness is usually self-limited, though a relapsing febrile course lasting months has been documented in some children.[2][3]
Rare but severe acute manifestations
Meningitis, encephalitis, myocarditis, pericarditis, acute acalculous cholecystitis, and isolated lymphadenitis have all been described; hemolytic uremic syndrome and rhabdomyolysis are additional rare pediatric presentations. Overall acute mortality is under 2%, though hospitalization rates can be high during large outbreaks (up to 50% during the 2007-2010 Netherlands outbreak).[2]
Post-Q fever fatigue syndrome
Up to 20% of patients with acute Q fever develop a debilitating fatigue syndrome — distinct from chronic Q fever endocarditis or osteomyelitis, with no identifiable organ involvement — that can persist for a year or, in some patients, for life. It typically affects previously healthy people and is a diagnosis of exclusion: organ involvement (i.e., true chronic Q fever) must be actively ruled out before attributing symptoms to this syndrome, since Q fever with organ involvement is antibiotic-responsive while post-Q fever fatigue syndrome has no evidence-based pharmacologic treatment.[2]
Risk Factors
- Occupational or hobby contact with cattle, sheep, or goats, especially around birthing — veterinarians and veterinary researchers, farmers (particularly sheep, goat, and dairy operations), abattoir/slaughterhouse workers, hide handlers, butchers, and laboratory personnel working with the organism or with infected animals.[3][2]
- Living in a rural area, on or near a farm housing livestock (particularly cattle, sheep, or goats), or in a suburban area near a farm or forested area — airborne spread has been documented for kilometres downwind of a source.[2][3]
- Consumption of unpasteurized ("raw") milk or dairy products.[3][1]
- Contact with a parturient pet, particularly cats and dogs — a well-documented, non-occupational source of North American outbreaks.[1][2]
- Recent travel to a region with a recent outbreak (e.g., the Netherlands, which had roughly 4,000 reported cases during 2007-2010) or to an area where Q fever is highly endemic (e.g., parts of the Middle East).[2]
- Sexual contact with a person recently diagnosed with Q fever, or contact with their contaminated clothing or linens (rare, but documented fomite and sexual transmission routes).[2][3]
- No identifiable exposure at all — most reported cases in North American surveillance data lack a recognized high-risk occupation or livestock contact, so a compatible clinical picture should not be dismissed for lack of an obvious source.[2]
- Risk factors specifically for progression to chronic disease after an acute infection (not for acquisition itself): pre-existing valvular heart disease, a vascular graft, or an arterial aneurysm; pregnancy; and immunosuppression (e.g., chemotherapy).[2][3]
- Age over 40 and male sex are both associated with a higher risk of symptomatic and more severe acute illness.[2]
Red Flags & Refer
Any of the following warrants urgent escalation — hospitalization, infectious diseases consultation, cardiology/echocardiography, or all three:
- New or worsening heart murmur, unexplained embolic phenomena, or unexplained fever, weight loss, night sweats, or fatigue in anyone with a history of Q fever and pre-existing valvular heart disease, a prosthetic valve, a vascular graft, or an arterial aneurysm — the median time from acute infection to endocarditis is 2.5 months, but it can present years to decades later, often with no prior recognized diagnosis of acute Q fever at all.[2]
- A pregnant patient with confirmed or suspected acute Q fever — refer for infectious diseases and high-risk obstetric input; up to 81% of untreated infected pregnant women may have an adverse pregnancy outcome, and the earlier in pregnancy infection occurs, the higher the risk for both fetal harm and maternal progression to chronic disease.[2][4]
- Neurologic findings (meningismus, altered mental status, encephalitis) or respiratory distress in a patient with a compatible febrile illness.[2]
- New fever or back pain in a patient with a known aortic aneurysm or vascular graft and any history of Q fever exposure — think vascular infection, which is frequently diagnosed only at the time of aortic rupture.[2]
- No clinical improvement, or persistent fever, more than 3-5 days after starting doxycycline for acute disease — reconsider the diagnosis or evaluate for a complication rather than simply extending the same regimen.[2]
- Any patient with a confirmed chronic Q fever diagnosis — this always warrants specialist (infectious diseases, and cardiology if endocarditis or vascular infection is suspected) involvement, given the multi-year treatment course and monitoring burden.[2][3]
Assessment & Diagnosis
Treat first, confirm in parallel
Because of the delay in seroconversion needed to confirm the diagnosis, antibiotic treatment for suspected acute Q fever should never be withheld pending laboratory results, nor discontinued on the basis of a single negative early test. Conversely, treatment for chronic Q fever should be started only after diagnostic confirmation — the two situations call for opposite defaults.[2][3]
History
Ask specifically about: contact with cattle, sheep, or goats — particularly around birthing, since the highest organism shedding occurs in birth products; consumption of unpasteurized milk or dairy; occupation (veterinary, farming, abattoir, laboratory); recent travel to an area with a known outbreak or high endemicity; and contact with a parturient pet. As above, the absence of any of these should not be used to exclude the diagnosis.[2][3]
Serologic testing — phase I versus phase II antibodies
C. burnetii exists in two antigenic phases that are central to diagnosis. Phase II is the avirulent laboratory-passage form; in acute infection, the antibody response to phase II antigen appears first and is initially higher than the phase I response. Phase I is the virulent, naturally-occurring form; in chronic infection, the phase I IgG antibody response continues to rise over time and can exceed the phase II response — a pattern that essentially never occurs in resolving acute infection.[2]
| Pattern | Acute Q fever | Chronic Q fever |
|---|---|---|
| Antibody response order | Phase II IgG rises first and is higher than phase I | Phase I IgG continues to rise over time and may equal or exceed phase II |
| Diagnostic serologic finding | Fourfold rise in phase II IgG by IFA between paired acute/convalescent sera taken 3-6 weeks apart; a single convalescent-phase II IgG titre ≥1:128 in a patient ill >1 week is considered probable | Rising or persistently elevated phase I IgG, typically ≥1:800 to ≥1:1024 depending on the criteria applied, plus an identifiable nidus of infection (e.g., endocarditis, vascular infection, osteomyelitis) |
| Typical clinical correlate | Self-limited febrile illness, atypical pneumonia, or hepatitis | Culture-negative endocarditis (60-78% of chronic cases), vascular infection, rarely osteomyelitis or chronic hepatitis |
A single elevated titre is not, by itself, diagnostic of anything. Because antibodies can remain detectable for months to years after resolved infection (baseline seroprevalence in the general population is roughly 3%), a single positive result — especially in a patient with a rural or farming background — does not confirm active infection, and treatment should not be started on a titre alone without a clinically compatible illness. The pregnancy-monitoring pathway below is the one deliberate exception to this rule.[2]
Other diagnostic tests
| Test | Notes |
|---|---|
| PCR (whole blood or serum) | Most useful in the first 2 weeks of acute illness, ideally drawn before or within 24-48 hours of starting antibiotics; becomes negative as the antibody response rises. In suspected chronic disease, PCR can also detect recurrent low-grade bacteremia and can be performed on excised valve tissue. |
| Immunohistochemistry | Detects C. burnetii antigen in formalin-fixed, paraffin-embedded tissue (notably excised heart valves) and remains positive even after antibiotic therapy has been given — useful for a retrospective diagnosis in unexplained culture-negative endocarditis or after valve-replacement relapse. |
| Culture / isolation | Not part of routine diagnosis. Requires a Biosafety Level 3 laboratory because of the organism's high infectivity and low infectious dose; a negative culture does not rule out infection, and routine hospital blood cultures will not detect C. burnetii at all. |
Chronic Q fever endocarditis — the Duke criteria and imaging
The revised Duke criteria for infective endocarditis define a phase I IgG antibody titre >1:800 (or a single positive blood culture for C. burnetii) as a major criterion. A transesophageal echocardiogram (TEE) is the recommended initial imaging study — more sensitive than transthoracic echocardiography — in any patient meeting this serologic criterion, since vegetations are visualized in only about 12% of confirmed cases and a negative echocardiogram (transthoracic or transesophageal) does not rule out chronic Q fever endocarditis.[2]
Routine blood cultures in Q fever endocarditis are always negative — this is one of the defining features of the disease, and it should specifically prompt Q fever serology in any patient being worked up for culture-negative endocarditis, alongside the other classic culture-negative organisms (Bartonella species, Brucella species, and the fastidious HACEK group).[2] For suspected vascular infection (an infected aneurysm or vascular graft), CT, MRI, or duplex ultrasound can identify the lesion, and FDG-PET/CT has high sensitivity and specificity for low-grade vascular infection and can reveal other infectious foci.[2]
Treatment Targets
- Start empiric doxycycline for suspected acute Q fever as soon as a clinically compatible illness is recognized, ideally within the first 3 days of symptoms — never wait for serology, which is often negative early and is primarily a retrospective confirmatory test.
- In pregnancy, use trimethoprim/sulfamethoxazole in place of doxycycline to reduce the risk of adverse fetal and pregnancy outcomes, which are otherwise common with untreated infection.
- Identify patients at risk for progression to chronic disease at the time of acute diagnosis (valvular heart disease, vascular graft, arterial aneurysm, immunosuppression, pregnancy) and route them into structured serologic follow-up.
- Diagnose chronic Q fever only with laboratory confirmation (a rising or persistently elevated phase I IgG titre) plus an identifiable nidus of infection — never treat "chronic Q fever" on the basis of an isolated elevated titre alone.
- Treat confirmed chronic Q fever/endocarditis with combination doxycycline plus hydroxychloroquine for a minimum of 18-24 months, with the monitoring intensity the regimen demands.
- Report confirmed and probable cases as required by the relevant provincial notifiable-disease framework.
Choose Initial Treatment
Doxycycline is first-line for adults, children ≥8 years, and severe illness at any age
Doxycycline 100 mg PO twice daily for 14 days is the most effective treatment for acute Q fever and is recommended for adults, children aged 8 years and older, and children of any age with severe illness. Treatment is most effective when started within the first 3 days of symptoms, but should still be given later if Q fever remains clinically suspected — it shortens the illness and reduces the risk of severe complications.[2][3]
Dosing by population
| Population | Regimen |
|---|---|
| Adults | 100 mg PO twice daily for 14 days |
| Children ≥8 years, or children <8 years who are high-risk (hospitalized/severe illness, pre-existing heart valvulopathy, immunocompromised, or delayed diagnosis with >2 weeks of unresolved symptoms) | 2.2 mg/kg/dose PO twice daily for 14 days (maximum 100 mg/dose) |
| Children <8 years with mild or uncomplicated illness | 2.2 mg/kg/dose PO twice daily for 5 days (maximum 100 mg/dose) — a course this short has not been shown to cause dental staining. If the child remains febrile beyond day 5, follow with trimethoprim/sulfamethoxazole for 14 days. |
Treatment for acute Q fever is not routinely recommended once symptoms have resolved, or for asymptomatic seropositive patients, though it may be considered in those already known to be at high risk for chronic disease.[2]
Doxycycline practical counselling points
Doxycycline may be taken with food to reduce stomach upset, but patients should avoid dairy products within 2 hours (before or after) of a dose, and should not take it with antacids or bismuth-containing products. Advise against lying down immediately after a dose (esophageal irritation risk). Doxycycline can cause photosensitivity and may reduce the efficacy of hormonal contraceptives.[2]
Alternatives if doxycycline is contraindicated by allergy (non-pregnant patients)
Alternatives moxifloxacin, clarithromycin, trimethoprim/sulfamethoxazole, and rifampin have all been used when doxycycline cannot be given because of allergy; the evidence base for each is considerably thinner than for doxycycline itself, and specialist input is reasonable before substituting.[2]
Use trimethoprim/sulfamethoxazole instead of doxycycline — this is not the same reasoning used for other tick/animal-associated rickettsial infections
Unlike anaplasmosis or ehrlichiosis, where doxycycline is used in pregnancy despite being a tetracycline because no equally effective alternative exists, Q fever has a proven, pathogen-specific reason to prefer a different drug in pregnancy. Doxycycline itself carries the standard tetracycline-class concern for fetal bone and dental effects (historically classified pregnancy category D). But more importantly, long-term trimethoprim/sulfamethoxazole treatment throughout pregnancy has been directly shown, in a cohort of pregnant women with acute Q fever, to significantly decrease the risk of adverse pregnancy outcomes compared with no treatment — up to 81% of untreated infected pregnant women had an adverse outcome, versus roughly 40% of those treated with long-term trimethoprim/sulfamethoxazole, and among the treated group, complications shifted toward the milder end of the spectrum (intrauterine growth restriction, preterm delivery) rather than stillbirth or miscarriage. Long-term treatment also reduced the mother's risk of progressing to chronic Q fever and reduced adverse events in subsequent pregnancies.[4][2]
| Regimen | Duration |
|---|---|
| Sulfamethoxazole/Trimethoprim 800 mg/160 mg (one double-strength tablet) PO twice daily | Throughout pregnancy — the Manitoba protocol specifies continuing until 32 weeks gestation, then discontinuing because of the risk of neonatal hyperbilirubinemia (kernicterus) with sulfonamide exposure near term. |
Because trimethoprim/sulfamethoxazole's antifolate effect has been associated with a possible increased risk of congenital abnormalities (primarily urinary tract and cardiovascular), concomitant folic acid supplementation is recommended for pregnant patients on this regimen.[2] A woman with a prior, more-than-30-days-before-conception Q fever infection and no evidence of chronic disease does not need treatment during a subsequent pregnancy — but pregnant women previously infected should be watched closely for recrudescent infection in every future pregnancy (see Special Populations).[2]
Doxycycline plus hydroxychloroquine, for a minimum of 18-24 months
Adults with confirmed chronic Q fever should receive combination therapy: Combo: doxycycline 100 mg PO twice daily + hydroxychloroquine 200 mg PO three times daily. The combination is necessary, not optional — hydroxychloroquine raises the pH of the acidified phagolysosome that C. burnetii lives inside, and in combination with doxycycline this restores the drug's activity from merely bacteriostatic to genuinely bactericidal against the organism in vitro. Doxycycline alone does not reliably eradicate chronic infection.[2]
| Manifestation | Minimum duration |
|---|---|
| Endocarditis, native valve | ≥18 months |
| Endocarditis, prosthetic valve | ≥24 months |
| Vascular infection (infected aneurysm or graft) | 18-24 months, similar to endocarditis; early surgical intervention may be needed if the patient does not respond to antibiotics alone |
| Postpartum with a chronic serologic profile (phase I IgG remaining ≥1:1024 more than 12 months after delivery, without an identified nidus) | 12 months |
Contraindications and precautions hydroxychloroquine is contraindicated in glucose-6-phosphate dehydrogenase (G6PD) deficiency and in patients with pre-existing retinal or visual field deficits. Both drugs can cause photosensitivity.[2]
Alternatives in children with chronic disease
Chronic Q fever is rare in children, and pediatric infectious diseases consultation is recommended. The safety of long-term hydroxychloroquine in children has not been established, and retinal-toxicity monitoring may be limited by a young child's ability to cooperate with colour-vision testing. Alternative regimens that have been considered include a fluoroquinolone (e.g., moxifloxacin or levofloxacin) combined with rifampin, or trimethoprim/sulfamethoxazole combined with doxycycline.[2]
Non-Pharmacologic Treatment
- Supportive care (hydration, antipyretics) alongside antibiotic therapy for acute disease; most cases can be managed as outpatients, with hospitalization reserved for severe presentations.
- No commercially available vaccine exists in Canada or the United States; a whole-cell vaccine (Q-VAX) is licensed only in Australia for defined high-risk occupational groups, since pre-vaccination screening is required to avoid a severe local reaction in previously exposed individuals.[2]
- Consume only pasteurized milk and dairy products.[3]
- Thorough hand hygiene after any contact with livestock, pets, or their birth products; appropriate disposal (incineration, composting, or burial per local regulation) of birth products and other organic animal waste.[3][2]
- Workers in high-risk occupations (veterinary, farming, abattoir, laboratory) should use appropriate personal protective equipment — gloves, protective clothing, and a fit-tested respirator — especially when assisting a birth or handling birth products, and should shower and change out of work clothing before leaving the workplace.[2]
- Post-exposure antimicrobial prophylaxis is not recommended after a known or potential exposure; instead, a daily fever-monitoring log for at least 3 weeks is advised, with immediate doxycycline and testing if fever develops.[2]
- Avoidance of "live cell therapy" or other xenotransplantation products of animal origin, which have caused documented Q fever outbreaks; no such products are approved for sale in Canada, but people do travel abroad to receive them.[3]
- Deferral of blood donation for two years following confirmed cure from acute infection should be considered for affected donors.[3]
- Report confirmed and probable cases per the relevant provincial requirement. Q fever is not a nationally notifiable disease in Canada, so national incidence data are not collected, but it is notifiable in several provinces, including Manitoba; it has been nationally notifiable in the United States since 1999.[3][2]
- No special isolation precautions are needed for routine care — Q fever is not spread by coughing, sneezing, or casual contact. Airborne precautions plus appropriate PPE (fit-tested N95 respirator, eye protection) are recommended specifically for aerosol-generating procedures in a patient with suspected or confirmed Q fever, such as an autopsy or the delivery of an infant from an infected woman.[2][3]
Special Populations
Children
Doxycycline is the drug of choice for acute Q fever at any age with severe illness, and is used without hesitation in children ≥8 years. For children under 8 with mild or uncomplicated illness, the shorter 5-day doxycycline course (which does not cause dental staining) is a reasonable option, escalating to 14 days of trimethoprim/sulfamethoxazole only if fever persists beyond day 5.[2][3] Note that trimethoprim/sulfamethoxazole is itself contraindicated in infants under 2 months of age.[3] Chronic Q fever is rare in children and, unlike in adults, most often presents as relapsing or multifocal osteomyelitis rather than endocarditis; pediatric infectious diseases consultation is recommended for any suspected pediatric chronic case.[2]
Pregnancy
Trimethoprim/sulfamethoxazole, not doxycycline, is the treatment of choice for acute Q fever diagnosed during pregnancy (see Choose Initial Treatment for the specific, pathogen-level rationale). Women infected during pregnancy are at meaningfully elevated risk for later chronic Q fever, and should be serologically and clinically monitored at 3, 6, 12, 18, and 24 months after delivery, regardless of whether treatment was given during pregnancy.[2][3] A woman previously infected during pregnancy who becomes pregnant again within this 24-month monitoring window should have Q fever serology resumed; a fourfold rise in IgG titre indicates recrudescent infection and warrants restarting long-term trimethoprim/sulfamethoxazole even without other localizing signs, since the presumed nidus of infection in this situation is the reproductive tract itself.[2] Chronic Q fever endocarditis developing during pregnancy is a genuine clinical dilemma, since the safety of the standard doxycycline-hydroxychloroquine regimen has not been evaluated in pregnancy — this requires infectious diseases and obstetric consultation.[2][3]
Breastfeeding
C. burnetii has been isolated from human breast milk, but no case of transmission to a breastfed infant via that route has been documented. This does not resolve the separate question of maternal drug safety during lactation — confirm any regimen against a current lactation-safety reference and the infant's own risk factors before dispensing.[2]
Immunosuppressed patients
Immunosuppression (e.g., from chemotherapy) is an independent risk factor for progression from acute to chronic disease, similar to pre-existing valvular or vascular disease — maintain closer serologic and clinical follow-up in this group.[2]
Occupational exposure
Post-exposure antibiotic prophylaxis is not recommended. Workers in high-risk occupations should be enrolled in a medical surveillance program where feasible, with a baseline serum sample and periodic testing for seroconversion, and should be counselled to seek immediate evaluation for any fever within about 6 weeks of a known or potential exposure.[2]
Renal and hepatic impairment
Doxycycline generally requires no dose adjustment in renal impairment. Hydroxychloroquine and rifampin should be used cautiously with attention to hepatic function, and any long-term combination regimen should be reviewed carefully for drug interactions, particularly given rifampin's potent enzyme-inducing effects if it is used as an alternative agent.
Monitoring & Follow-Up
Acute disease
- Expect defervescence within about 72 hours of starting doxycycline; if fever persists beyond 3-5 days, reconsider the diagnosis or evaluate for a complication.[2]
- Complete the full 14-day course even after symptoms resolve.
Risk-stratified follow-up after acute infection
During treatment for chronic Q fever
- Monthly serologic testing (phase I and II IgG and IgM by IFA) and monthly clinical evaluation.[2][3]
- If an adequate treatment response is not being achieved, add monthly monitoring of serum drug levels: hydroxychloroquine, target 0.8-1.2 µg/mL; doxycycline, target ≥5 µg/mL.[2]
- Baseline ophthalmic examination before starting hydroxychloroquine, repeated every 6 months for the duration of treatment, given the risk of retinal toxicity with long-term use.[2]
- There is no single, universally accepted serologic "cure" cutoff usable in North American labs; rather than chasing a specific titre, use the trend of a decreasing phase I IgG together with ongoing clinical recovery to judge response. A patient treated appropriately for ≥18 months who has recovered clinically but whose phase I IgG remains persistently elevated may not benefit from further extending treatment — this decision should involve an infectious diseases specialist.[2]
- After completing treatment, continue serologic monitoring twice yearly for a minimum of 5 years; lifelong monitoring may be warranted in patients with severe underlying valvular disease.[2]
Common Errors to Avoid
- Withholding empiric doxycycline for suspected acute Q fever while waiting for serology — confirmatory testing requires paired samples 3-6 weeks apart and is primarily retrospective; early treatment is what shortens illness and reduces severe complications.[2]
- Excluding the diagnosis because the patient reports no direct animal contact — most reported cases lack a recognized occupational exposure or livestock contact, since airborne transmission from birth products can travel kilometres from the source.[2]
- Reflexively avoiding doxycycline in pregnancy for the same generic "tetracyclines are teratogenic" reasoning used for other rickettsial diseases, without recognizing that Q fever specifically has a proven-effective, pathogen-specific alternative (long-term trimethoprim/sulfamethoxazole) with real outcome data behind it — this is a genuinely different situation from anaplasmosis or ehrlichiosis, where doxycycline itself remains preferred in pregnancy.[4][2]
- Treating chronic Q fever with doxycycline alone — doxycycline monotherapy is only bacteriostatic against C. burnetii; hydroxychloroquine is required to achieve bactericidal activity by raising phagolysosomal pH.[2]
- Stopping chronic Q fever treatment based on an arbitrary or borrowed titre cutoff rather than the trend of a declining phase I IgG together with genuine clinical recovery — no single commercially available cutoff is standardized for this purpose in North America.[2]
- Diagnosing or retreating "chronic Q fever" based on a single elevated phase I or phase II titre without an identifiable nidus of infection and a compatible clinical picture — antibodies can persist for months to years after resolved acute infection.[2]
- Assuming a negative echocardiogram excludes Q fever endocarditis — vegetations are seen in only about 12% of confirmed cases, and a negative TTE or TEE does not rule out the diagnosis in a patient who otherwise meets the Duke serologic criterion.[2]
- Missing Q fever as a cause of culture-negative endocarditis — routine blood cultures are always negative in this disease; it belongs on the same differential as Bartonella, Brucella, and the HACEK organisms whenever standard cultures come back negative in suspected endocarditis.[2]
- Skipping the baseline and 6-monthly ophthalmologic examination during hydroxychloroquine therapy, or omitting the G6PD-deficiency and retinal-disease contraindication check before starting it.[2]
- Forgetting to add folic acid when prescribing long-term trimethoprim/sulfamethoxazole in pregnancy, given its antifolate mechanism.[2]
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
First-Line Therapy — Acute Q Fever, Non-Pregnant Patients
Start as soon as a clinically compatible illness is recognized. Do not withhold pending serology.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Doxycycline | Adults: 100 mg PO twice daily for 14 days Children ≥8 years, or <8 years if high-risk (severe illness, hospitalized, pre-existing valvulopathy, immunocompromised, or delayed diagnosis): 2.2 mg/kg/dose PO twice daily for 14 days, maximum 100 mg/dose Children <8 years, mild/uncomplicated illness: 2.2 mg/kg/dose PO twice daily for 5 days, maximum 100 mg/dose; add trimethoprim/sulfamethoxazole x14 days if still febrile past day 5 | GI upset, photosensitivity, esophageal irritation if taken without adequate fluid; short 5-day courses do not stain permanent teeth | Reduced absorption with antacids, calcium, iron, bismuth, or dairy taken simultaneously; may reduce hormonal contraceptive efficacy | Most effective within the first 3 days of symptoms, though still indicated later if Q fever remains clinically suspected |
Pregnancy-Specific Therapy — Acute Q Fever
Replaces doxycycline in pregnancy specifically because of proven Q fever pregnancy-outcome benefit, not simply reflexive tetracycline avoidance.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Sulfamethoxazole/Trimethoprim | Adults: 800 mg/160 mg (one double-strength tablet) PO twice daily, throughout pregnancy until 32 weeks gestation, then discontinued | Antifolate effects; near-term use carries a risk of neonatal hyperbilirubinemia/kernicterus | Additive antifolate effect with other folate antagonists; monitor INR if used with warfarin | Co-administer folic acid throughout treatment given the antifolate mechanism |
| Folic acid | Adults: Standard prenatal supplementation dose per product monograph | Well tolerated | None clinically significant at supplementation doses | Given specifically to offset the antifolate effect of concurrent trimethoprim/sulfamethoxazole therapy |
Chronic Q Fever / Endocarditis Combination Therapy
Doxycycline alone is only bacteriostatic against C. burnetii. Hydroxychloroquine raises phagolysosomal pH, converting the combination to bactericidal activity in vitro — this is why monotherapy is not an acceptable substitute.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Doxycycline | Adults: 100 mg PO twice daily for ≥18 months (native valve) or ≥24 months (prosthetic valve); 12 months for a postpartum chronic serologic profile | GI upset, photosensitivity, esophageal irritation | Reduced absorption with antacids, calcium, iron, dairy | Target serum level (if response is inadequate): ≥5 µg/mL |
| Hydroxychloroquine | Adults: 200 mg PO three times daily for the same duration as the paired doxycycline course | Retinal toxicity with long-term use; GI upset; photosensitivity | Additive QTc-prolonging effect with other QTc-prolonging drugs; contraindicated in G6PD deficiency | Baseline ophthalmic examination before starting, repeated every 6 months for the duration of treatment; target serum level 0.8-1.2 µg/mL if response is inadequate; safety in children not established |
Alternative Therapy — Doxycycline Allergy or Intolerance
Reserve for confirmed doxycycline allergy or severe intolerance. Evidence for Q fever specifically is considerably thinner than for doxycycline; specialist consultation is reasonable.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Rifampin | Adults and children: Specialist-directed dosing | Hepatotoxicity, orange discolouration of body fluids, GI upset | Potent CYP3A4/2C9 inducer — reduces levels of many co-administered drugs, including warfarin and hormonal contraceptives | Used for doxycycline allergy in acute disease, or paired with a fluoroquinolone/TMP-SMX for chronic disease in children |
| Moxifloxacin | Adults and children: Specialist-directed dosing | Tendinopathy/tendon rupture, QTc prolongation, dysglycemia | Additive QTc prolongation with other QTc-prolonging drugs | Alternative for acute disease with doxycycline allergy; combined with rifampin as an alternative pediatric chronic-disease regimen |
| Levofloxacin | Children: Specialist-directed dosing | Tendinopathy/tendon rupture, QTc prolongation, dysglycemia | Additive QTc prolongation with other QTc-prolonging drugs | Alternative to moxifloxacin, paired with rifampin, for pediatric chronic disease |
| Clarithromycin | Adults and children: Specialist-directed dosing | GI upset, QTc prolongation, metallic taste | Potent CYP3A4 inhibitor — numerous significant interactions | Alternative for acute disease with doxycycline allergy |
| Ofloxacin | Adults: Specialist-directed dosing | Tendinopathy/tendon rupture, QTc prolongation, dysglycemia | Additive QTc prolongation with other QTc-prolonging drugs | Historically reported in combination with doxycycline as an alternative chronic-disease regimen |
References
- Pathogen Safety Data Sheets: Infectious Substances – Coxiella burnetii — Public Health Agency of Canada. Government of Canada, Public Health Agency of Canada, updated November 2010
- Diagnosis and Management of Q Fever — United States, 2013: Recommendations from CDC and the Q Fever Working Group — MMWR Recommendations and Reports, Centers for Disease Control and Prevention (Anderson A, Bijlmer H, Fournier PE, et al.). MMWR Recomm Rep 2013;62(RR-3):1-30
- Communicable Disease Management Protocol – Q Fever — Manitoba Health, Healthy Living and Seniors. Government of Manitoba, April 2016
- Managing Q Fever During Pregnancy: The Benefits of Long-Term Cotrimoxazole Therapy — Clinical Infectious Diseases (Carcopino X, Raoult D, Bretelle F, Boubli L, Stein A). Clin Infect Dis 2007;45(5):548-555
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.